Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021
Esther Kissling, Mariëtte Hooiveld, Iván Martínez‐Baz, Clara Mazagatos, Naoma William, Ana‐Maria Vilcu, Marjolein N. Kooijman, Maja Ilić, Lisa Domegan, Ausenda Machado, Simon de Lusignan, Mihaela Lazăr, Adam Meijer, Mia Brytting, Itziar Casado, Amparo Larrauri, Josie Murray, Sylvie Behillil, Brechje de Gier, Ivan Mlinarić, Joan O’Donnell, Ana Paula Rodrigues, Ruby S. M. Tsang, Olivia Carmen Timnea, Marit de Lange, Maximilian Rieß, Jesús Castilla, Francisco Pozo, Mark Hamilton, Alessandra Falchi, Mirjam J. Knol, Sanja Filipović, Linda Dunford, Raquel Guiomar, Jade Cogdale, Carmen Maria Cherciu, Tessa Jansen, Theresa Enkirch, Luca Basile, Jeff Connell, Verónica Gomez, Virginia Martin, Sabrina Bacci, Angela Rose, Lucia Pastore Celentano, Marta Valenciano, I-MOVE-COVID-19 and ECDC primary care study teams
Abstract
IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.ResultsOverall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.ConclusionsVE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.